Literature DB >> 31084273

HMGB1 inhibits insulin signalling through TLR4 and RAGE in human retinal endothelial cells.

Youde Jiang1, Jena J Steinle1.   

Abstract

In the past decade, the role of inflammation has been shown in diabetes and its complications. Little is available on high mobility group box 1 (HMGB1) actions on the proteins involved in insulin signal transduction, which may be altered to result in insulin resistance in the retina. Retinal endothelial cells (REC) were grown in normal or high glucose and treated with recombinant human HMGB1, an Epac1 agonist, or both. Additional cells were treated with advanced glycation end-products (RAGE) or toll-like receptor 4 (TLR4) siRNA prior to rhHMGB1. Proteins lysates were processed for Western blotting for TLR4, RAGE, insulin receptor, Akt, and IRS-1 phosphorylation. We found that rhHMGB1 blocked insulin and Akt phosphorylation through either RAGE or TLR4 actions. Epac1 overcame both endogenous and exogenous HMGB1 to maintain normal insulin signalling. Taken together, these data offer upstream targets to maintain proper insulin signal transduction in the retinal vasculature.

Entities:  

Keywords:  HMGB1; RAGE; Retinal endothelial cells; TLR; insulin receptor; signalling

Mesh:

Substances:

Year:  2018        PMID: 31084273      PMCID: PMC6521723          DOI: 10.1080/08977194.2018.1539393

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  29 in total

1.  TNFα and SOCS3 regulate IRS-1 to increase retinal endothelial cell apoptosis.

Authors:  Youde Jiang; Qiuhua Zhang; Carl Soderland; Jena J Steinle
Journal:  Cell Signal       Date:  2012-01-12       Impact factor: 4.315

Review 2.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.

Authors:  Michael T Lotze; Kevin J Tracey
Journal:  Nat Rev Immunol       Date:  2005-04       Impact factor: 53.106

3.  Characterization of insulin signaling in rat retina in vivo and ex vivo.

Authors:  Chad E N Reiter; Lakshman Sandirasegarane; Ellen B Wolpert; Marianne Klinger; Ian A Simpson; Alistair J Barber; David A Antonetti; Mark Kester; Thomas W Gardner
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-06-10       Impact factor: 4.310

4.  Insulin infusion suppresses while glucose infusion induces Toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients.

Authors:  Paresh Dandona; Husam Ghanim; Kelly Green; Chang Ling Sia; Sanaa Abuaysheh; Nitesh Kuhadiya; Manav Batra; Sandeep Dhindsa; Ajay Chaudhuri
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-12       Impact factor: 4.310

Review 5.  High-mobility group box 1 (HMGB1) protein: friend and foe.

Authors:  Luis Ulloa; Davorka Messmer
Journal:  Cytokine Growth Factor Rev       Date:  2006-03-02       Impact factor: 7.638

6.  High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina.

Authors:  Ghulam Mohammad; Mohammad Mairaj Siddiquei; Amira Othman; Mohamed Al-Shabrawey; Ahmed M Abu El-Asrar
Journal:  Exp Eye Res       Date:  2012-12-21       Impact factor: 3.467

7.  Differential roles of hyperglycemia and hypoinsulinemia in diabetes induced retinal cell death: evidence for retinal insulin resistance.

Authors:  Patrice E Fort; Mandy K Losiewicz; Chad E N Reiter; Ravi S J Singh; Makoto Nakamura; Steven F Abcouwer; Alistair J Barber; Thomas W Gardner
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

8.  Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissue.

Authors:  Brice Nativel; Mery Marimoutou; Vincent G Thon-Hon; Manoj Kumar Gunasekaran; Jessica Andries; Giovédie Stanislas; Cynthia Planesse; Christine Robert Da Silva; Maya Césari; Thomas Iwema; Philippe Gasque; Wildriss Viranaicken
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

9.  Cytoplasmic translocation of high-mobility group box-1 protein is induced by diabetes and high glucose in retinal pericytes.

Authors:  Junghyun Kim; Chan-Sik Kim; Eunjin Sohn; Jin Sook Kim
Journal:  Mol Med Rep       Date:  2016-09-02       Impact factor: 2.952

10.  Epac1 agonist decreased inflammatory proteins in retinal endothelial cells, and loss of Epac1 increased inflammatory proteins in the retinal vasculature of mice.

Authors:  Li Liu; Youde Jiang; Adam Chahine; Elizabeth Curtiss; Jena J Steinle
Journal:  Mol Vis       Date:  2017-01-25       Impact factor: 2.367

View more
  5 in total

1.  Loss of TLR4 in endothelial cells but not Müller cells protects the diabetic retina.

Authors:  Adam Seidel; Li Liu; Youde Jiang; Jena J Steinle
Journal:  Exp Eye Res       Date:  2021-03-28       Impact factor: 3.467

2.  Effects of Glycyrrhizin Treatment on Diabetic Cornea.

Authors:  Mallika Somayajulu; Sharon A McClellan; Ahalya Pitchaikannu; Denise Bessert; Li Liu; Jena Steinle; Linda D Hazlett
Journal:  J Ocul Pharmacol Ther       Date:  2020-12-21       Impact factor: 2.671

3.  Ammonium Glycyrrhizinate Prevents Apoptosis and Mitochondrial Dysfunction Induced by High Glucose in SH-SY5Y Cell Line and Counteracts Neuropathic Pain in Streptozotocin-Induced Diabetic Mice.

Authors:  Laura Ciarlo; Francesca Marzoli; Paola Minosi; Paola Matarrese; Stefano Pieretti
Journal:  Biomedicines       Date:  2021-05-26

4.  Downregulation of Lysosomal Acid Ceramidase Mediates HMGB1-Induced Migration and Proliferation of Mouse Coronary Arterial Myocytes.

Authors:  Xinxu Yuan; Owais M Bhat; Hannah Lohner; Yang Zhang; Pin-Lan Li
Journal:  Front Cell Dev Biol       Date:  2020-03-10

Review 5.  High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives.

Authors:  Federico Biscetti; Maria Margherita Rando; Elisabetta Nardella; Andrea Leonardo Cecchini; Giovanni Pecorini; Raffaele Landolfi; Andrea Flex
Journal:  Int J Mol Sci       Date:  2019-12-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.